Elmhurst, NY, United States of America

Nigel Yarlett

This inventor holds 2 USPTO granted patents. Top assignees: Health Research, Inc., Pace University. Active years: 1993-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nigel Yarlett. Retrieved from https://idiyas.com/inventor/nigel-yarlett

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1993-1996

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Nigel Yarlett: Pioneering Advancements in Therapeutic Compounds

Introduction

Nigel Yarlett, an accomplished inventor based in Elmhurst, NY, has made significant contributions to the field of medicinal chemistry. He is recognized for his innovative work in developing compounds that target pathogenic microorganisms and neoplastic diseases, showcasing a commitment to advancing healthcare.

Latest Patents

Yarlett holds two notable patents that highlight his groundbreaking research on 5'-deoxy-5'-(substituted)alkylthioribose compounds. These include the following compounds: 5'-deoxy-5'-(hydroxyethylthio)adenosine (HETA), 5'-deoxy-5'-(monofluoroethylthio)adenosine (MFETA), 5'-deoxy-5'-(chloroethylthio)adenosine (CETA), and 5'-deoxy-5'-(bromoethylthio)adenosine (BETA). Additionally, he has developed variants such as 5-deoxy-5-(monofluoroethylthio)ribose (MFETR), 5-deoxy-5-(chloroethylthio)ribose (CETR), 5-deoxy-5-(bromoethylthio)ribose (BETR), and 5-deoxy-5-(hydroxyethylthio)ribose (HETR). These compounds demonstrate potential uses in treating infections caused by pathogenic microorganisms that possess 5'-deoxy-5'-methylthioadenosine (MTA) phosphorylase and 5-deoxy-5-methylthioribose (MTR) kinase, along with providing therapeutic options for neoplastic diseases.

Career Highlights

Throughout his career, Yarlett has been affiliated with prominent organizations such as Health Research, Inc. and Pace University. His work within these institutions has allowed him to advance his research and collaborate with various experts in the field.

Collaborations

Yarlett has worked alongside notable coworkers Janice R. Sufrin and Cyrus J. Bacchi. Their collaboration has been instrumental in refining and implementing solutions based on the innovative compounds he has developed.

Conclusion

Nigel Yarlett is a distinguished inventor whose contributions to the field of therapeutic compounds are paving the way for new treatment options against pathogenic infections and neoplastic diseases. His ongoing dedication to research and collaboration significantly impacts the medical community, highlighting the transformative potential of innovative inventions in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…